Abstract
Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood-brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when it is used as a first line of therapy compared with gefitinib and erlotinib. It is also efficient as second-line therapy for patients who developed the T790M resistance mutation following treatment with previous generation TKIs. Here, we report 11 patients who were treated by an increasing dose of osimertinib from 80 mg to 160 mg QD orally following intracranial progression in either first- or second-line setting. This is a subcohort analysis from a larger nonrandomized, phase 2, open-label trial, evaluating the efficacy of osimertinib dose escalation from 80 mg to 160 mg in EGFR-mutated advanced non-small-cell lung cancer (NSCLC) patients with intracranial progression in either first- (arm A) or second-line setting (arm B for T790M+ and C for T790M-). Eleven patients, 5 in arm A, 4 in arm B, and 2 in arm C were reported in this study. The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2...Continue Reading
References
Mar 17, 2000·Journal of Neuro-oncology·P D SchellingerA Thron
Mar 2, 2005·PLoS Medicine·William PaoHarold Varmus
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takayuki KosakaTetsuya Mitsudomi
Nov 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marissa N BalakWilliam Pao
Jan 7, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nir PeledFred R Hirsch
Aug 8, 2014·Journal of Neuro-oncology·Ling CaiLan-jun Zhang
Aug 7, 2017·Journal of Neuro-oncology·Mengxi GeQiong Zhan
Oct 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christine CordovaMatija Snuderl
Aug 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thanyanan ReungwetwattanaJohan Vansteenkiste
Oct 20, 2018·Current Cancer Drug Targets·Yuanyuan SongYuankai Shi
Dec 5, 2018·Cancer·Myung-Ju AhnGlenwood Goss
Aug 11, 2019·BMC Cancer·Yanxin ChenAnwen Liu
Oct 8, 2019·The Lancet Oncology·Myung-Ju AhnByoung Chul Cho
Oct 24, 2019·Asia-Pacific Journal of Clinical Oncology·Maverick Wai-Kong Tsang
Nov 22, 2019·The New England Journal of Medicine·Suresh S RamalingamUNKNOWN FLAURA Investigators
Dec 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C H YangMyung-Ju Ahn
Dec 31, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Myung-Ju AhnTony Mok
Feb 13, 2020·World Journal of Clinical Cases·Hui-Ying LiZhen-Yu Yin